journal article·2024-08-21

Targeted Inhibition of Lymphovascular Invasion Formation with CREKA Peptide-Modified Silicasomes to Boost Chemotherapy in Bladder Cancer

Zhouliang Wu, Bozhao Li, Yunkai Qie, Suying Wu, Feilong Qi, Tianjiao Chu, Guangjun Nie, Hailong Hu

Nano Letters· Volume 24· Issue 33
Publisher page

Abstract

Despite its significant clinical efficacy as a first-line treatment for advanced bladder cancer, cisplatin-based chemotherapy provides a limited benefit for patients with lymphovascular invasion (LVI), which is characterized by the presence of tumor emboli within blood vessels and associated with enhanced cisplatin resistance and metastatic potential. Notably, platelets, a critical component of LVI, hinder the delivery of chemotherapeutic agents to tumors and facilitate metastasis. Consequently, platelet function inhibition holds the potential to disrupt LVI formation, as well as augment the antitumor activity of cisplatin. Herein, we developed a tumor microenvironment-targeted nanodrug with lipid-coated mesoporous silica nanoparticles (silicasomes) that synergistically combines cisplatin with an antiplatelet agent, tirofiban, for bladder cancer treatment. The customized nanodrug can concurrently prevent LVI formation and enhance the chemotherapeutic efficacy without significant adverse effects. This study supports the integration of chemotherapy and antiplatelet therapy via a silicasome-based nanosystem as a highly promising strategy for bladder cancer management.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bladder and Urothelial Cancer Treatments · Inflammatory Biomarkers in Disease Prognosis · Urinary and Genital Oncology Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin 300211, China

CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China

Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China

Funding

National Key Research and Development Program of China · China Postdoctoral Science Foundation · Second Hospital of Tianjin Medical University

References (51)

Show source-provided references
1. 10.1016/S0140-6736(16)30512-810.1016/S0140-6736(16)30512-8 ↗
2. 10.3322/caac.2149210.3322/caac.21492 ↗
3. 10.1016/j.bioactmat.2020.08.01910.1016/j.bioactmat.2020.08.019 ↗
4. 10.1016/j.eururo.2021.08.01010.1016/j.eururo.2021.08.010 ↗
5. 10.1200/JCO.2005.07.75710.1200/JCO.2005.07.757 ↗
6. 10.1200/JCO.2015.65.979710.1200/JCO.2015.65.9797 ↗
7. 10.1016/j.eururo.2021.09.02810.1016/j.eururo.2021.09.028 ↗
8. 10.1016/j.critrevonc.2015.05.00510.1016/j.critrevonc.2015.05.005 ↗
9. 10.1186/s13046-015-0282-y10.1186/s13046-015-0282-y ↗
10. 10.1002/1097-0142(19951115)76:10<1772::AID-CNCR2820761014>3.0.CO;2-O10.1002/1097-0142(19951115)76:10<1772::AID-CNCR2820761014>3.0.CO;2-O ↗
11. 10.1200/JCO.2008.17.236110.1200/JCO.2008.17.2361 ↗
12. 10.1093/annonc/mdq33310.1093/annonc/mdq333 ↗
13. 10.1111/j.1365-2559.2009.03425.x10.1111/j.1365-2559.2009.03425.x ↗
14. 10.1016/j.euf.2018.09.01910.1016/j.euf.2018.09.019 ↗
15. 10.1038/nprot.2010.18910.1038/nprot.2010.189 ↗
16. 10.1038/nbt.407110.1038/nbt.4071 ↗
17. 10.1158/0008-5472.CAN-11-187210.1158/0008-5472.CAN-11-1872 ↗
18. 10.1182/blood-2013-03-49244710.1182/blood-2013-03-492447 ↗
19. 10.1038/s41551-017-0115-810.1038/s41551-017-0115-8 ↗
20. 10.1038/s41577-019-0202-z10.1038/s41577-019-0202-z ↗
21. 10.1038/nature0679710.1038/nature06797 ↗
22. 10.1038/nrcardio.2017.20610.1038/nrcardio.2017.206 ↗
23. 10.1002/adma.20110476310.1002/adma.201104763 ↗
24. 10.1002/anie.20140200210.1002/anie.201402002 ↗
25. 10.1021/acs.nanolett.1c0016810.1021/acs.nanolett.1c00168 ↗
26. 10.1073/pnas.061029810410.1073/pnas.0610298104 ↗
27. 10.1016/j.biomaterials.2015.11.06110.1016/j.biomaterials.2015.11.061 ↗
28. 10.1002/adma.20190679910.1002/adma.201906799 ↗
29. 10.1038/s41598-017-18466-910.1038/s41598-017-18466-9 ↗
30. 10.1016/S0022-5347(05)00526-410.1016/S0022-5347(05)00526-4 ↗
31. 10.1016/j.ijsu.2015.03.00510.1016/j.ijsu.2015.03.005 ↗
32. 10.1016/j.ijsu.2018.03.08410.1016/j.ijsu.2018.03.084 ↗
33. 10.1111/bju.1299710.1111/bju.12997 ↗
34. 10.1007/s12282-010-0211-z10.1007/s12282-010-0211-z ↗
35. 10.1002/jhbp.49910.1002/jhbp.499 ↗
36. 10.1016/j.healun.2015.03.00410.1016/j.healun.2015.03.004 ↗
37. 10.1016/j.jcis.2019.05.07110.1016/j.jcis.2019.05.071 ↗
38. 10.1021/acsnano.5b0051010.1021/acsnano.5b00510 ↗
39. 10.1182/blood-2005-04-153010.1182/blood-2005-04-1530 ↗
40. 10.1182/blood-2010-07-29771310.1182/blood-2010-07-297713 ↗
41. 10.1016/S0140-6736(17)30770-510.1016/S0140-6736(17)30770-5 ↗
42. 10.1080/10717544.2017.137894010.1080/10717544.2017.1378940 ↗
43. 10.1186/s12951-023-01827-010.1186/s12951-023-01827-0 ↗
44. 10.1002/adma.20210995510.1002/adma.202109955 ↗
45. 10.1084/jem.2019186910.1084/jem.20191869 ↗
46. 10.1038/s41467-021-23086-z10.1038/s41467-021-23086-z ↗
47. 10.7150/thno.1790810.7150/thno.17908 ↗
48. 10.1038/s41467-017-01837-110.1038/s41467-017-01837-1 ↗
49. 10.1007/s13238-020-00701-110.1007/s13238-020-00701-1 ↗
50. 10.1021/acsnano.1c0602210.1021/acsnano.1c06022 ↗
51. 10.1016/j.apsb.2020.11.01410.1016/j.apsb.2020.11.014 ↗